生物体液中候选RNA标志物用于卵巢癌早期诊断的系统综述
卵巢癌常晚期确诊且死亡率高,缺乏有效早期筛查方法。本系统综述汇总了75种可在人体生物体液中检测的RNA标志物,多数为血液中经RT-qPCR或微阵列检测的microRNA。至少两项独立研究一致显示卵巢癌患者生物体液中miR-21、miR-200家族、miR-205、miR-10a和miR-346更丰富,而miR-122、miR-193a、miR-223、miR-126和miR-106b更低。这些标志物有诊断潜力,但常规临床应用前需进一步验证。
要点
- 系统综述汇总75种生物体液RNA标志物用于卵巢癌早期诊断。
- 多数标志物为血液microRNA,经RT-qPCR或微阵列检测。
- miR-21、miR-200家族等至少两项研究一致升高,miR-122等一致降低。
核心结论
- 多种生物体液RNA标志物对卵巢癌早期诊断有前景,但尚未达到常规临床应用标准。
研究设计与样本
- 系统综述,汇总75种可在人体生物体液中检测的RNA标志物,多数为血液microRNA,经RT-qPCR或微阵列检测,少数研究使用RNA测序并探索尿液和腹水。
主要发现
- 至少两项独立研究一致显示卵巢癌患者生物体液中miR-21、miR-200家族、miR-205、miR-10a和miR-346更丰富。
- 至少两项研究确认miR-122、miR-193a、miR-223、miR-126和miR-106b在卵巢癌患者生物体液中更低。
临床怎么用
- 目前这些RNA标志物不宜用于常规临床早期诊断,需进一步验证。
局限性
- 多数标志物基于血液microRNA和RT-qPCR或微阵列,使用RNA测序及尿液、腹水的研究较少。
- 候选标志物需进一步验证后才能常规临床应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ovarian cancer is often diagnosed in an advanced stage and is associated with a high mortality rate. It is assumed that early detection of ovarian cancer could improve patient outcomes. Unfortunately, effective screening methods for early diagnosis of ovarian cancer are still lacking. Extracellular RNAs circulating in human biofluids can reliably be measured and are emerging as potential biomarkers in cancer. In this systematic review, we present 75 RNA biomarkers detectable in human biofluids that have been studied for early diagnosis of ovarian cancer. The majority of these markers are microRNAs identified using RT-qPCR or microarrays in blood-based fluids. A handful of studies used RNA-sequencing and explored alternative fluids, such as urine and ascites. Candidate RNA biomarkers that were more abundant in biofluids of ovarian cancer patients compared to controls in at least two independent studies include miR-21, the miR-200 family, miR-205, miR-10a and miR-346. Amongst the markers confirmed to be lower in at least two studies are miR-122, miR-193a, miR-223, miR-126 and miR-106b. While these biomarkers show promising diagnostic potential, further validation is required before implementation in routine clinical care. Challenges related to biomarker validation and reflections on future perspectives to accelerate progress in this field are discussed.
引用
- Hulstaert E, Morlion A, Levanon K, et al. Candidate RNA biomarkers in biofluids for early diagnosis of ovarian cancer: A systematic review. Gynecol Oncol. 2020. PMID: 33257015. doi:10.1016/j.ygyno.2020.11.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。